Form 4: Neogenomics General Counsel Alicia C. Olivo Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Alicia C. Olivo, General Counsel of Neogenomics, sold 1,040 shares of common stock at $16.0533 per share on August 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 15, 2024, Alicia C. Olivo, General Counsel of Neogenomics Inc., sold 1,040 shares of common stock at a price of $16.0533 per share.
- The sale was executed under a Rule 10b5-1 trading plan.
- Following the transaction, Ms. Olivo directly owns 43,813 shares of Neogenomics common stock, which includes 125 shares acquired through the company's Employee Stock Purchase Plan (ESPP).
- Ms. Olivo also holds various stock options and restricted stock units (RSUs) that represent the right to buy or receive shares of Neogenomics common stock at different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was conducted under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook on the company.
Positives
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing Ms. Olivo's transactions to those of other General Counsels in similar-sized biotech companies would provide a benchmark for assessing the significance of this sale.
- For example, if other General Counsels are also selling shares under 10b5-1 plans, it could indicate a broader trend of diversification or personal financial planning.
- Conversely, if Ms. Olivo's sale is significantly larger than those of her peers, it could raise concerns about her confidence in the company's future prospects.
Stakeholder Impact
- The sale of shares by a company insider could potentially create uncertainty among shareholders, although the use of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/30/2019 | Ms. Olivo was granted 1,394 stock options. |
| 05/01/2020 | Ms. Olivo was granted 1,024 stock options. |
| 05/01/2021 | Ms. Olivo was granted 516 stock options. |
| 08/01/2021 | Ms. Olivo was granted 1,117 stock options. |
| 05/01/2022 | Ms. Olivo was granted 22,222 stock options. |
| 09/01/2022 | Ms. Olivo was granted 55,332 stock options. |
| 05/11/2023 | Ms. Olivo was granted 36,508 stock options, 19,508 performance stock units, and 19,508 restricted stock units. |
| 02/23/2024 | Ms. Olivo was granted 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units. |
| 08/15/2024 | Ms. Olivo sold 1,040 shares of common stock. |
| 08/19/2024 | Date of the Form 4 filing. |
| 05/11/2026 | Expiration date for performance stock units granted on May 11, 2023. |
| 02/23/2027 | Expiration date for performance stock units granted on February 23, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.